GB-102 (Reyon Pharmaceutical)

GB-102 is an experimental gene therapy candidate being developed by Reyon Pharmaceutical (이연제약). It is designed to deliver genetic material encoding both Vascular Endothelial Growth Factor (VEGF) and Hepatocyte Growth Factor (HGF) to promote angiogenesis and facilitate tissue regeneration. The drug is currently under investigation for the treatment of various conditions including chronic renal failure (chronic kidney disease), ischemic heart disease (coronary artery disease), and breast cancer. By expressing these specific growth factors, GB-102 aims to restore vascular function and repair damaged tissues in patients with cardiovascular and renal impairments. The product is part of Reyon Pharmaceutical's strategic focus on regenerative medicine and is currently in Phase 1 clinical development.